**CHEMOTHERAPY FOUNDATION SYMPOSIUM XXV**

**INNOVATIVE CANCER TREATMENT FOR TOMORROW**

**CLINICAL AND RESEARCH ADVANCES**

**UPDATE ON THERAPEUTIC AGENTS**

- **Hematology**
  - Clofarabine
  - CP-4057
  - Donor Stem Cells
  - Donor Lymphocytes
  - Fludarabine
  - Galacizumab
  - Imatinib
  - Lenalidomide
  - Palbociclib
  - Pioglitazone
  - Tamoxifen
  - Tadalafil

- **Solid Tumors**
  - Abemaciclib
  - Axitinib
  - Carisoprodol
  - Cabercept
  - Cabozantinib
  - Cabozantinib
  - Cabozantinib
  - Cabozantinib
  - Cabozantinib

- **Biologic Malignancies**
  - Novel Therapeutics: AML
  - Flavopiridol in AML, ALL
  - Azacitidine in AML
  - Treating the Elderly
  - Angiogenesis Inhibitors in CLL
  - Oral Kinase Inhibitors
  - EGFR Inhibitors
  - Axitinib
  - Gleevec
  - Histone Deacetylase Inhibitors

**GI CANCERS: TRIALS AND TACTICS**

- Advanced CRC: Biologic Agents & Targeted Therapies
- Prognostic Micro-RNA in Pancreatic Cancer
- CRC: A Novel Combination
- Angiogenesis Inhibitors in CRC
- Exploring Selective In CRC Regimens
- RAS-1: An Antihuman Antibody
- S1-1 in Gastric Cancer
- Pancreatic Cancer: Prognostic Micro-RNA’s
- Biologic Inhibitors in Upper GI Cancers
- Hepatocellular Carcinoma: Advances
- Recat Cancer: Chemoradiation with New Agents
- GST: Treatment Update
- Radioimmunotherapy: Liver Metastases
- A Neuroanatomic Indicator

**GVH DISEASE & HEAD & NECK CANCER UPDATE**

- New Agents
- Regulated Liposomal Doxorubicin
- Diagonal & Predictive Markers
- Intraperitoneal Delivery in Ovarian Cancer
- Cervical Cancer: Socio-Medical Indicators
- GOG Update

**CURRENT & FUTURE TARGETED THERAPIES**

- Clofarabine
- Azacitidine
- Asparaginase
- AZ2171
- Lenalidomide in MDS
- Asparaginase Efficacy in ALL
- Oral Agent in CLL/ALL
- Kinase Inhibitors in CLL

**NAB-Paclitaxel**

- NAB-Paclitaxel
- Mapatumumab
-Ixabepilone
- EM-1421
- Tyrosine Kinase Inhibitors

**MANAGEMENT OF MULTIPLE CYTOPENIAS**

- Inhibitors: Erythropoietins
- EGFR Inhibitors
- Aurora Kinase Inhibitors
- Angiogenesis Inhibitors

**LCM INFECTIONS**

- Micro-RNA’s: Pancreatic Cancer
- Response Prediction: Breast & Lung Cancer
- Cancer Stem Cells

**EMERGING THERAPIES IN HEMATOLOGY**

- Tuesday, November 6
  - Dinner & Special Presentations: PEDIATRIC ONCOLOGY ADVANCES IN 2007

**NEW TAXANE ALTERNATIVES**

- Friday, November 9
  - Lunch & Special Presentations: ADVANCES IN TREATMENT OF HORMONE REFRACTORY PROSTATE CANCER

**SPECIAL PRESENTATIONS & HOSTED EVENTS**

- **HEMATOLOGIC MALIGNANCIES**
  - Advances in Multiple Myeloma
  - High Risk MDs/PDX
  - ReluXimab-based Regimens
  - Plasma Cell Dyscrasias
  - IMo & MAB
  - Combination Therapies
  - Endothelin
  - Radioimmunotherapy

**HEMATOLOGIC MALIGNANCIES**

- Novel Therapeutics: AML
- Flavopiridol in AML, ALL
- Azacitidine in AML
- Treating the Elderly
- Angiogenesis Inhibitors in CLL
- Oral Kinase Inhibitors
- EGFR Inhibitors
- Axitinib
- Gleevec
- Histone Deacetylase Inhibitors

**GYN CANCERS: MEETING THE CHALLENGE**

- New Studies
- Update on Terampecol
- Employing An Antitumor Agent

**LUNG CANCER TOPICS**

- Novel Three-Agent Combination
- Biomarkers: Emerging Developments
- Fish/Elution Data
- Amrubicin & US & EU Studies in SCLC
- An Oral Inhibitor
- Sunitinib: A Targeted Therapy in NSCLC
- Non-small Cell Lung Cancer

**GLIOMASTOMAS: NEW DIRECTIONS**

- Update on Terampecol
- Employing An Antitumor Agent

**OCUCONEICOGONICS**

- Micro-RNA’s: Pancreatic Cancer
- Response Prediction: Breast & Lung Cancer
- Cancer Stem Cells
New Perspectives in Oncology Practice
Presented by Reed Medical Education
Saturday, November 10, 8 AM - 4 PM
Empowering the Clinical Care Team
A Continuing Education Program for Oncology Nurses, Physician Assistants, Case Managers

ACCREDITATION

Physicians

The Mount Sinai School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Mount Sinai School of Medicine designates this educational activity for a maximum of 31.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity applicable only to the Tuesday through Friday, November 6-9, 2007 sessions.

Oncology Nurses, PA’s, Case Managers

CME hours for the Tuesday through Friday sessions (November 6-9) may be awarded to prelicensing organizations for acceptance of credit to CE. Authorized CME credit hours for Saturday, November 10 will be determined by accredited organizations. Applications are pending for submission to Established Mosby, an accredited provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation, the American Academy of Physician Assistants and the Commission for Case Manager Certification.

Pharmacists

Pharmacists will be eligible for a maximum of 31 CEU’s for their attendance at the Tuesday through Friday sessions and 7 additional CEUs for the Saturday session from an authorized ACCP provider. Application to NPSHP-NCI pending.

Verification of Attendance will be provided to all professionals.

FACULTY DISCLOSURE POLICY

The Mount Sinai School of Medicine requires all faculty, planners, and other persons in a position to control the content of an educational activity to disclose all financial relationships with ineligible companies. All planners and faculty must identify to the audience any relevant relationships and financial interests that may have influenced or be perceived to influence the development of the activity.

The Mount Sinai School of Medicine has reviewed and intends to resolve any conflicts of interest that may arise as a result of this educational activity. The planners and faculty have been advised that resolving conflicts is a process designed to help ensure that the weight of evidence presented is balanced, independent, transparent and scientific and that all educational content is unbiased.

The Mount Sinai School of Medicine is committed to maintaining balance, independence, transparency and scientific rigor in all CME sponsored educational activities. All faculty participating in the planning or implementation of a supported activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict-of-interest that may arise from the situation. Presenters must also have a meaningful disclosures to the audience in their discussions of unapproved, off label, or unproven uses of devices.

This information will be available as part of the course material.

THE CHEMOTHERAPY FOUNDATION

The Mount Sinai School of Medicine has organized a scientific educational laboratory and clinical research projects at major medical institutions, symposia for the profession, and publishes informative booklets for the profession and the public. Tax-deductible contributions may be sent to 183 Madison Avenue, New York, NY 10016.

PROFESSIONAL MEMBERSHIP in the CHEMOTHERAPY FOUNDATION

Upon registration, a professional may request a list of current symposia, indicated in the following: 15% for the Saturday program to be determined.

The chemotherapy Foundation Newsletter including information on new professional educational opportunities, new publications and other current Foundation activities.

Send check or money order for $50 to

President’s CME Program: FID

The Mount Sinai School of Medicine requires all faculty, planners, and other persons in a position to control the content of an educational activity to disclose all financial relationships with ineligible companies. All planners and faculty must identify to the audience any relevant relationships and financial interests that may influence or be perceived to influence the development of the activity.

The Mount Sinai School of Medicine has reviewed and intends to resolve any conflicts of interest that may arise as a result of this educational activity. The planners and faculty have been advised that resolving conflicts is a process designed to help ensure that the weight of evidence presented is balanced, independent, transparent and scientific and that all educational content is unbiased.

The Mount Sinai School of Medicine is committed to maintaining balance, independence, transparency and scientific rigor in all CME sponsored educational activities. All faculty participating in the planning or implementation of a supported activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict-of-interest that may arise from the situation. Presenters must also have a meaningful disclosures to the audience in their discussions of unapproved, off label, or unproven uses of devices.

This information will be available as part of the course material.

CONFERENCE HIGHLIGHTS

EZRAGRISANPEXPERIMENTAL THERAPY & SKIN

NEW YORK ONCOLOGY EDUCATIONAL ALLIANCE

SUNY Downstate Medical Center

Long Island Jewish Medical Center

NYU Medical Center

New Perspectives in Oncology Practice
Presented by Reed Medical Education
Saturday, November 10, 8 AM - 4 PM
Empowering the Clinical Care Team
A Continuing Education Program for Oncology Nurses, Physician Assistants, Case Managers

Symposium Clinical Advisory Board
Howard Burris III, M.D., Sarah Cannon Cancer Center
Edward Chu, M.D., Yale Cancer Center
Nicolete Colombo, M.D., European Institute of Oncology
Anna Ferrari, M.D., Long Island Jewish Medical Center
John Holland, M.D., Mount Sinai Medical Center

New Perspectives in Oncology Practice
Presented by Reed Medical Education
Saturday, November 10, 8 AM - 4 PM
Empowering the Clinical Care Team
A Continuing Education Program for Oncology Nurses, Physician Assistants, Case Managers